Ginkgo medicine for recent ischemic stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if a specific ginkgo-based medicine (Ginkgo Diterpene Lactone Meglumine) can help people who had an ischemic stroke within the last 48 hours. It looks at whether taking this drug improves recovery compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You had an ischemic stroke (a type of stroke caused by a clot) in the last 48 hours
- You or your legal representative can agree to join the study
- You did not have a disability score of 2 or more on the mRS scale before the stroke (this measures how much help you need with daily activities)
- You will be in the hospital for at least 7 days after the stroke
- You are not taking any other ginkgo products during the study, and you are not in another clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a ginkgo biloba extract supplement can help improve thinking and memory after a stroke. It is for people who recently had a stroke and have some mild to moderate memory problems, but are not already taking other memory medications.
This trial tests an investigational drug called LT3001 for people who have had an acute ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). The drug is given within 24 hours of the stroke to help reduce the damage and improve recovery. Participating could offer access to a new treatment option that may help improve outcomes.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This trial tests a new medicine (glenzocimab) given along with standard clot-removal procedure for people who had a stroke with a large area of brain damage. The goal is to see if the medicine helps improve recovery.
This trial tests whether an SGLT2 inhibitor (a diabetes medicine) can protect the brain after a recent moderate-to-severe ischemic stroke. It may help reduce damage and improve recovery.
This study tests an experimental drug called BB-031 to see if it can safely help people who have had a recent ischemic stroke (a clot that blocks blood flow to the brain). The trial is for people who can get to the hospital within 24 hours of their first symptoms and have a moderate to severe stroke.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.